Acyclovir

国际站：Acyclovir

中文名：阿昔洛韦

CAS：59277-89-3

品牌：MedChemExpress (MCE)

存储条件：Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.

生物活性：阿昔洛韦 (Aciclovir) 是一种有效的口服活性抗病毒剂。阿昔洛韦具有抗疱疹活性，对 HSV-1 和 HSV-2 的 IC₅₀ 值为 0.85 μM 和 0.86 μM ， 分别。 Acyclovir 诱导细胞周期扰动和细胞凋亡。阿昔洛韦预防急性白血病诱导治疗期间的细菌感染^[1][2][3][4] . 

体外：阿昔洛韦（阿昔洛韦，3-100 µM；24-72 小时；Jurkat、U937 和 K562 白血病细胞）以剂量和时间依赖性方式降低细胞活力^[1]。阿昔洛韦（阿昔洛韦，10-100 µM；24-72 小时；Jurkat 细胞）阻断 DNA 合成，从而使细胞周期停滞在 G2/M 和 S 期，并以剂量依赖的方式增加亚 G1 亚二倍体峰^{[ 1]}.阿昔洛韦（Aciclovir, 10-100 µM; 24-72 hours; Jurkat cells）通过激活caspase-3并存在核DNA片段化诱导细胞凋亡^[1] .

体内：阿昔洛韦（20 mg/kg；口服；每日三次；持续 10 天；BALB/c 小鼠）治疗受感染小鼠可抑制皮肤损伤的发展，并导致 DTH 反应与抗体产生之间的分离^[1]。

参考文献：[1]. Benedetti S, et, al. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells, and enhances chemotherapeutic drug cytotoxicity. Life Sci. 2018 Dec 15;215:80-85.[2]. Suzuki M, et, al. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2006 Nov;72(2):157-61.[3]. Li Z, et, al. Acyclovir treatment of skin lesions results in immune deviation in mice infected cutaneously with herpes simplex virus. Antivir Chem Chemother. 1999 Sep;10(5):251-7.[4]. Lönnqvist B, et, al. Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer. 1993 May;1(3):139-44.